H
Hans-Beat Ris
Researcher at University Hospital of Lausanne
Publications - 222
Citations - 7346
Hans-Beat Ris is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Pneumonectomy & Thoracoscopy. The author has an hindex of 42, co-authored 219 publications receiving 6791 citations. Previous affiliations of Hans-Beat Ris include École Polytechnique Fédérale de Lausanne & University of Bern.
Papers
More filters
Journal ArticleDOI
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial
Daniel Betticher,Shu Fang Hsu Schmitz,Martin Tötsch,Eva Hansen,Christine Joss,Christian von Briel,Ralph A. Schmid,Miklos Pless,James Habicht,Arnaud Roth,Anastase Spiliopoulos,Rolf A. Stahel,Walter Weder,Roger Stupp,Fritz Egli,Markus Furrer,Hanspeter Honegger,M. Wernli,Thomas Cerny,Hans-Beat Ris +19 more
TL;DR: Neoadjuvant docetaxel-cisplatin is effective and tolerable in stage IIIA pN2 NSCLC and downstaging to N0-1 at surgery was prognostic and significantly prolonged event-free survival (EFS) and overall survival (OS).
Journal ArticleDOI
Risk Factors for Survival after Lung Metastasectomy in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Michel Gonzalez,Antoine Poncet,Christophe Combescure,John Robert,Hans-Beat Ris,Pascal Gervaz +5 more
TL;DR: Clinical variables associated with prolonged survival after surgery for LM in CRC patients include prolonged disease-free interval between primary tumor and metastatic spread, normal prethoracotomy carcinoembryonic antigen, absence of thoracic node involvement, and a single pulmonary lesion.
Journal ArticleDOI
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Walter Weder,R. Stahel,Jürg Bernhard,Stephan Bodis,Peter Vogt,Pierluigi Ballabeni,Didier Lardinois,Daniel C. Betticher,Ralph A. Schmid,Roger Stupp,Hans-Beat Ris,Monika Jermann,W Mingrone,Arnaud Roth,Anastase Spiliopoulos +14 more
TL;DR: A median survival of 23 months for patients undergoing EPP compares favourably with the survival reported from single center studies of upfront surgery, and the observed rate of operability is promising.
Journal ArticleDOI
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Miklos Pless,Roger Stupp,Roger Stupp,Hans-Beat Ris,Rolf A. Stahel,Walter Weder,Sandra Thierstein,Marie-Aline Gérard,A. Xyrafas,Martin Früh,Richard Cathomas,Alfred Zippelius,Arnaud Roth,Milorad Bijelovic,Adrian F. Ochsenbein,Urs R. Meier,Christoph Mamot,Daniel Rauch,Oliver Gautschi,Daniel Betticher,René O. Mirimanoff,Solange Peters +21 more
TL;DR: It is suggested that one definitive local treatment modality combined with neoadjuvant chemotherapy is adequate to treat resectable stage IIIA/N2 non-small-cell lung cancer.
Journal ArticleDOI
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results.
Hans-Beat Ris,H. J. Altermatt,R. Inderbitzi,R. Hess,B. Nachbur,J. C. M. Stewart,Q. Wang,Chang Kee Lim,Raymond Bonnett,M. C. Berenbaum +9 more
TL;DR: Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma and one patient succumbed from aspiration pneumonia.